Compare NNDM & AGMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NNDM | AGMB |
|---|---|---|
| Founded | 2012 | 2017 |
| Country | United States | Belgium |
| Employees | 468 | N/A |
| Industry | Electrical Products | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 606.7M | 576.2M |
| IPO Year | 2015 | 2024 |
| Metric | NNDM | AGMB |
|---|---|---|
| Price | $1.41 | $8.38 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $37.67 |
| AVG Volume (30 Days) | ★ 1.4M | 139.5K |
| Earning Date | 11-18-2026 | 11-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $102,437,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $6.00 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 77.30 | N/A |
| 52 Week Low | $1.19 | $7.97 |
| 52 Week High | $2.32 | $17.82 |
| Indicator | NNDM | AGMB |
|---|---|---|
| Relative Strength Index (RSI) | 33.08 | 31.21 |
| Support Level | $1.19 | N/A |
| Resistance Level | $1.64 | $12.53 |
| Average True Range (ATR) | 0.05 | 0.81 |
| MACD | -0.02 | 0.01 |
| Stochastic Oscillator | 12.00 | 13.95 |
Nano Dimension Ltd provides industrial manufacturing solutions for the design-to-manufacturing of electronics and mechanical parts. These solutions are based on a combination of hardware, software, and materials science technologies. The solutions include industrial machinery, such as those for additive manufacturing, surface-mount technology, and industrial inkjet printing, along with software for design, simulation, and manufacturing management, as well as materials or consumables that are used by the machinery. These solutions are used by industrial customers in aerospace & defense, automotive, electronics, medical, research, and academia, along with government organizations.
AgomAb Therapeutics NV is a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for immunology and inflammatory diseases, with an initial focus on chronic fibrotic indications with high unmet medical need. Its product candidates are designed to target established pathways and utilize validated modalities, with a focus on addressing limitations associated with prior treatment approaches. The company's pipeline includes small molecule and antibody product candidates aimed at targets associated with fibrotic diseases. Key candidates include Ontunisertib (AGMB-129) and AGMB-447.